Gardasil® 9 protects against nine types of human papillomavirus (HPV) infection. HPV types 6 and 11 cause anogenital warts and HPV types 16, 18, 31, 33, 45, 52, 58 can cause persistent infection leading to mouth, throat, cervical, vaginal, vulvar, penile and anal cancers. The Ministry of Health information pamphlet Immunise against HPV (code HE2012) is available from www.healthed.govt.nz. The pamphlet is also available electronically in Chinese Simplified, Chinese Traditional, Cook Islands Māori, Hindi, Māori, Sāmoan, and Tongan.
Nimenrix® is a meningococcal A,C,Y,W-135 conjugate vaccine used to protect against four groups of Neisseria meningitidis, group A, group C, group Y and group W-135.
Nimenrix® is used as an alternative vaccine to the meningococcal C conjugate vaccine (Neisvac-C™), meningococcal A,C,Y,W-135 conjugate vaccine (Menactra®) and the meningococcal A,C,Y,W-135 polysaccharide vaccine (Mencevax® ACYW).
The conjugate and polysaccharide vaccines work differently to generate protection against the bacteria. Protection from the conjugate vaccines lasts longer than that from the polysaccharide vaccines. The conjugate vaccines also generate long term memory cells allowing rapid boosting of immunity years later.
Scientists at the Malaghan Institute of Medical Research in Wellington have made significant progress in the basic research required to develop a vaccine against asthma and allergy.
Explaining the principle behind this vaccine Institute Director Professor Graham Le Gros said “We don’t know why the immune systems of individuals with asthma or food allergy respond to house dust mites and food proteins as though they were parasites. But what we do know from our research is that if we shut down the Th2 immune response before it gets going, we can prevent the development of asthma and allergy symptoms”.
The work at the Malaghan Institute complements past research that showed a decrease in allergy and asthma symptoms in young children who had received immunisation against some infectious diseases when compared with their unimmunised peer group.
IPOL is used for primary and booster vaccination of infants, children and adults to protect against infection with Type 1, Type 2 and Type 3 polioviruses causing poliomyelitis.
Pneumovax® 23 is used to protect against disease caused by 23 types of Streptococcus pneumoniae.
M-M-R® II is used for primary vaccination and revaccination of children and adults to protect against measles, mumps and rubella.
ADT™ Booster is used for primary and booster vaccination of children 7 years of age and over and adults to protect against tetanus and diphtheria. An alternative vaccine called Boostrix®, which protects against tetanus, diphtheria and pertussis (whooping cough), can be substituted for one, two or all three doses of the primary vaccinations in these age groups. Both ADT™ Booster and Boostrix® are licensed as booster vaccines. They are used for primary vaccination out of licensure as there is no alternative primary vaccination strength vaccine available in New Zealand for these age groups. When the vaccine is used for a primary vaccination course, use will be outside of current licensure. No safety concerns are expected with use in these circumstances.
Infanrix®-IPV is used for primary and booster vaccination of infants and children to protect against diphtheria, tetanus, pertussis and poliomyelitis. Infanrix®-IPV can also be used for catch-up immunisation for children up to their 10th birthday.
Gardasil® protects against four types of human papillomavirus (HPV) infection. HPV types 6 and 11 cause anogenital warts and HPV types 16 and 18 can cause persistent infection leading to mouth, throat, cervical, vaginal, vulvar, penile and anal cancers.
Infanrix®-hexa is used for primary and booster vaccination of infants and children to protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type b. Infanrix®-hexa can also be used for catch-up immunisation for children up to their 10th birthday.